Boston Scientific continues acquisition trail
This article was originally published in Clinica
Boston Scientific is to acquire Meadox Medicals in a stock deal valued at $425 million. Subject to regulatory approval, the merger is expected to be completed in the fourth quarter of 1995, making it Boston Scientific's fifth acquisition this year. The Natick, Massachusetts-based company will offer up to 10.5 million common shares for Meadox Medicals, a privately-held company estimated to hold some 80% of the US market for vascular replacement or repair devices.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.